Next-generation platform integrates multi-modal data to enhance cancer diagnostics and clinical decision-making
1Cell.Ai has announced the launch of OncoIncytes, a next-generation AI-powered platform designed to transform precision oncology through advanced multi-modal data integration. The launch represents a significant milestone in the company’s evolution, combining cutting-edge artificial intelligence with deep biological insights to improve cancer diagnostics and treatment strategies.
OncoIncytes brings together multiple layers of biological data; including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), RNA transcriptomics, and proteomics– at single-cell resolution. This integrated approach enables a more comprehensive understanding of tumor heterogeneity and disease progression, allowing clinicians and researchers to make more informed, data-driven decisions.
The platform is powered by a robust AI engine capable of analyzing complex datasets to identify clinically relevant patterns that may not be detectable through conventional methods. With applications spanning early detection, therapy selection, treatment monitoring, and clinical trial optimization, OncoIncytes aims to address critical gaps in oncology care. Its high-sensitivity capabilities also support minimal residual disease (MRD) detection, a key factor in predicting relapse and improving long-term patient outcomes.
The launch of OncoIncytes also aligns with the company’s strategic transition from OneCell Diagnostics to 1Cell.Ai, reflecting a broader vision centered on the convergence of artificial intelligence and precision medicine. By leveraging scalable AI infrastructure alongside validated genomic panels, the company is positioning itself at the forefront of next-generation oncology solutions.
Leadership at 1Cell.Ai emphasized that the platform is designed not only for technological advancement but also for accessibility- bridging the gap between complex molecular diagnostics and real-world clinical application. As precision oncology continues to evolve, solutions like OncoIncytes are expected to play a pivotal role in enabling personalized cancer care at scale.
Media Coverage